Home
MNPR
MNPR News

Latest Monopar Therapeutics Inc. (MNPR) News on May 31, 2025

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

GlobeNewswire

18 days ago

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

GlobeNewswire

25 days ago

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

Why Monopar Therapeutics Inc. (MNPR) is Surging in 2025

Insider Monkey

a month ago

Why Monopar Therapeutics Inc. (MNPR) is Surging in 2025

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

GlobeNewswire

a month ago

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

Argus Research

2 months ago

Daily – Vickers Top Buyers & Sellers for 04/07/2025

We Think Monopar Therapeutics (NASDAQ:MNPR) Can Easily Afford To Drive Business Growth

Simply Wall St.

2 months ago

We Think Monopar Therapeutics (NASDAQ:MNPR) Can Easily Afford To Drive Business Growth

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments

GlobeNewswire

2 months ago

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments

Why Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025

Insider Monkey

4 months ago

Why Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025

Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics

PR Newswire

4 months ago

Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics

Monopar Therapeutics price target raised to $40 from $22 at H.C. Wainwright

TipRanks

4 months ago

Monopar Therapeutics price target raised to $40 from $22 at H.C. Wainwright

MT Newswires

5 months ago

Piper Sandler Initiates Monopar Therapeutics at Overweight With $72 Price Target

MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN

Zacks

5 months ago

MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN

These 2 Monster Growth Stocks Skyrocketed Over 1,000% This Year — Here’s What Analysts Expect in 2025

TipRanks

5 months ago

These 2 Monster Growth Stocks Skyrocketed Over 1,000% This Year — Here’s What Analysts Expect in 2025

What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

Zacks

5 months ago

What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

MT Newswires

5 months ago

Monopar Therapeutics Prices $40 Million Offering, Private Placement

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

GlobeNewswire

5 months ago

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

MT Newswires

6 months ago

Monopar Therapeutics Shares Jump After First Patient Dosed in Cancer Therapy

Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

GlobeNewswire

6 months ago

Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

GlobeNewswire

6 months ago

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

GlobeNewswire

7 months ago

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

MT Newswires

7 months ago

Monopar Therapeutics Closes $19.2 Million Common Stock Offering

Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

GlobeNewswire

7 months ago

Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

MT Newswires

7 months ago

Monopar Therapeutics Prices Best Efforts Public Offering at $16.25 per Share

Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

GlobeNewswire

7 months ago

Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock

GlobeNewswire

7 months ago

Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock

Individual investors are Monopar Therapeutics Inc.'s (NASDAQ:MNPR) biggest owners and were rewarded after market cap rose by US$40m last week

Simply Wall St.

7 months ago

Individual investors are Monopar Therapeutics Inc.'s (NASDAQ:MNPR) biggest owners and were rewarded after market cap rose by US$40m last week

Monopar Therapeutics Secures License for Wilson Disease Treatment

TipRanks

7 months ago

Monopar Therapeutics Secures License for Wilson Disease Treatment

MT Newswires

7 months ago

Top Midday Gainers

Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate

GlobeNewswire

7 months ago

Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate

Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024

GlobeNewswire

7 months ago

Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024

Monopar Therapeutics Expands Portfolio with New Patent Filing

TipRanks

7 months ago

Monopar Therapeutics Expands Portfolio with New Patent Filing

Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers

GlobeNewswire

8 months ago

Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers

Monopar Therapeutics Launches Phase 1a uPAR-Targeted Cancer Trial

TipRanks

8 months ago

Monopar Therapeutics Launches Phase 1a uPAR-Targeted Cancer Trial

Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers

GlobeNewswire

8 months ago

Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers

MT Newswires

9 months ago

Sector Update: Health Care Stocks Rise in Thursday Trading

MT Newswires

9 months ago

Top Midday Gainers

MT Newswires

9 months ago

Monopar Therapeutics Says Early Data Validate Potential Cancer Treatment; Shares Jump

Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr

GlobeNewswire

9 months ago

Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr

Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire

9 months ago

Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule

GlobeNewswire

9 months ago

Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule

MT Newswires

9 months ago

Monopar Receives Clearance in Australia for Phase 1 Trial of Radiopharmaceutical in Advanced Cancers

Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers

GlobeNewswire

9 months ago

Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers

Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr

GlobeNewswire

10 months ago

Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr

Here's Why We're Watching Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation

Simply Wall St.

10 months ago

Here's Why We're Watching Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation

Upcoming Stock Splits This Week (August 12 to August 16) – Stay Invested

TipRanks

10 months ago

Upcoming Stock Splits This Week (August 12 to August 16) – Stay Invested

Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments

GlobeNewswire

10 months ago

Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments

Monopar Therapeutics Announces 1-for-5 Reverse Stock Split

GlobeNewswire

10 months ago

Monopar Therapeutics Announces 1-for-5 Reverse Stock Split

Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr

GlobeNewswire

a year ago

Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr

Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24

GlobeNewswire

a year ago

Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24

Monopar and NorthStar Amend & Extend Collaboration

GlobeNewswire

a year ago

Monopar and NorthStar Amend & Extend Collaboration

Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting

GlobeNewswire

a year ago

Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting

MT Newswires

a year ago

Monopar Therapeutics Names Karthik Radhakrishnan as CFO

Monopar Announces CFO Succession

GlobeNewswire

a year ago

Monopar Announces CFO Succession

Bears are Losing Control Over Monopar Therapeutics (MNPR), Here's Why It's a 'Buy' Now

Zacks

a year ago

Bears are Losing Control Over Monopar Therapeutics (MNPR), Here's Why It's a 'Buy' Now

Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline

GlobeNewswire

a year ago

Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline

Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

GlobeNewswire

a year ago

Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings

GlobeNewswire

a year ago

Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings

Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

GlobeNewswire

a year ago

Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

Monopar Therapeutics (MNPR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Zacks

a year ago

Monopar Therapeutics (MNPR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy

Zacks

a year ago

All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

GlobeNewswire

a year ago

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

GlobeNewswire

a year ago

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial

GlobeNewswire

a year ago

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial

Here's Why We're Watching Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation

Simply Wall St.

a year ago

Here's Why We're Watching Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation

Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers

GlobeNewswire

a year ago

Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers

Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers

GlobeNewswire

a year ago

Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers

LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2024

GlobeNewswire

a year ago

LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2024

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology

GlobeNewswire

a year ago

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology

OSS and FLYHT Expand Relationship with the Design and Manufacturing of 5G Enabled AFIRS(TM) Edge Solution

ACCESSWIRE

a year ago

OSS and FLYHT Expand Relationship with the Design and Manufacturing of 5G Enabled AFIRS(TM) Edge Solution

Novo Integrated Sciences Reports Fiscal Year 2024 First Quarter Financial Results

Business Wire

a year ago

Novo Integrated Sciences Reports Fiscal Year 2024 First Quarter Financial Results

Banzai Executes LOI to Acquire Cliently, An AI-Driven Sales Engagement Platform

GlobeNewswire

a year ago

Banzai Executes LOI to Acquire Cliently, An AI-Driven Sales Engagement Platform

Alarum Technologies Ltd. Featured in Syndicated Broadcast Covering Preliminary Q4 2023 Results Pointing Towards All Time High Operating Cashflow and Revenue

GlobeNewswire

a year ago

Alarum Technologies Ltd. Featured in Syndicated Broadcast Covering Preliminary Q4 2023 Results Pointing Towards All Time High Operating Cashflow and Revenue

ReWalk Robotics Expands Direct Sales Coverage to Canada

GlobeNewswire

a year ago

ReWalk Robotics Expands Direct Sales Coverage to Canada

Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference

GlobeNewswire

a year ago

Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference

Nova Vision Acquisition Corp. Announces Additional Contribution to Trust Account to Extend Period to Consummate Business Combination to February 10, 2024

GlobeNewswire

a year ago

Nova Vision Acquisition Corp. Announces Additional Contribution to Trust Account to Extend Period to Consummate Business Combination to February 10, 2024

United-Guardian Appoints New Director

GlobeNewswire

a year ago

United-Guardian Appoints New Director

GlobeNewswire

a year ago

Performance Shipping Inc. Secures Two Year Time Charter Contract With Oil Major at US$37,200 Per Day

Sunrise New Energy Secures Highly Regarded Japanese Patent for Invention of Lithium-Ion Battery Anode Material Preparation Method

GlobeNewswire

a year ago

Sunrise New Energy Secures Highly Regarded Japanese Patent for Invention of Lithium-Ion Battery Anode Material Preparation Method

GlobeNewswire

a year ago

Performance Shipping Inc. Signs Shipbuilding Contracts for the Construction of 2 Newbuilding LNG-Ready Scrubber Fitted Tier III LR2 Tankers

RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

Business Wire

a year ago

RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

GlobeNewswire

a year ago

Performance Shipping Inc. Announces Full Prepayment of Piraeus Bank S.A. Loans and Significant Reduction of Finance Costs

Metalpha Announces Official Uplift of Type 4 License

PR Newswire

a year ago

Metalpha Announces Official Uplift of Type 4 License

GreenPower Delivers Four Nano BEAST All-Electric, School Buses to West Virginia School Districts

CNW Group

a year ago

GreenPower Delivers Four Nano BEAST All-Electric, School Buses to West Virginia School Districts

GlobeNewswire

a year ago

Performance Shipping Inc. Announces Completion of Sale and Delivery of 2007 Built M/T P. Kikuma to New Owners

CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone

GlobeNewswire

a year ago

CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone

News Direct

a year ago

ProSomnus CEO Len Liptak unveils game-changing device and promising clinical trial results for 2024

GlobeNewswire

a year ago

Performance Shipping Inc. Issues 2022 Sustainability Report

Kaival Brands Appoints James W. Dobbins as Senior Vice President, General Counsel

GlobeNewswire

a year ago

Kaival Brands Appoints James W. Dobbins as Senior Vice President, General Counsel

Uzma and Satellogic Sign Multi-Million Dollar +3-Year Agreement to Advance Geospatial Capabilities in Southeast Asia

Business Wire

a year ago

Uzma and Satellogic Sign Multi-Million Dollar +3-Year Agreement to Advance Geospatial Capabilities in Southeast Asia

GlobeNewswire

2 years ago

Performance Shipping Inc. Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2023

GlobeNewswire

2 years ago

Performance Shipping Inc. Announces Filing of Amendment No. 2 to the Solicitation and Recommendation Statement on Schedule 14D-9

GlobeNewswire

2 years ago

Performance Shipping Inc. Announces the Sale of 2007 Built M/T P. Kikuma for US$39.3 Million

Iridex to Host Third Quarter Financial Results Conference Call on November 14, 2023

GlobeNewswire

2 years ago

Iridex to Host Third Quarter Financial Results Conference Call on November 14, 2023

Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2023 Earnings Call Transcript

HAMILTON BEACH BRANDS HOLDING COMPANY DECLARES QUARTERLY DIVIDEND AND ANNOUNCES STOCK REPURCHASE PROGRAM

PR Newswire

2 years ago

HAMILTON BEACH BRANDS HOLDING COMPANY DECLARES QUARTERLY DIVIDEND AND ANNOUNCES STOCK REPURCHASE PROGRAM

ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results

GlobeNewswire

2 years ago

ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results

Monopar Therapeutics Inc Reports Q3 2023 Financial Results and Progress in Clinical Programs

GuruFocus.com

2 years ago

Monopar Therapeutics Inc Reports Q3 2023 Financial Results and Progress in Clinical Programs

Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments

GlobeNewswire

2 years ago

Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments

Associated Press Finance

2 years ago

Blend Labs: Q3 Earnings Snapshot

Creative Realities Named a 2023 Digital Signage Experience Awards (DIZZIE) Finalist

GlobeNewswire

2 years ago

Creative Realities Named a 2023 Digital Signage Experience Awards (DIZZIE) Finalist

Share on Social Networks: